Luteoloside |
A flavanoid with diverse biological activities; reduces LDH and caspase-3… |
25 mg |
25141-25 |
More Info
|
Luteoloside |
A flavanoid with diverse biological activities; reduces LDH and caspase-3… |
5 mg |
25141-5 |
More Info
|
Luteoloside |
A flavanoid with diverse biological activities; reduces LDH and caspase-3… |
50 mg |
25141-50 |
More Info
|
Luteoreticulin |
A nitro-containing bacterial metabolite; has mosquitocidal activity agains… |
2.5 mg |
25515-25 |
More Info
|
Luteoreticulin |
A nitro-containing bacterial metabolite; has mosquitocidal activity agains… |
500 µg |
25515-500 |
More Info
|
Luzindole |
A melatonin receptor antagonist that preferentially targets MT1B over MT1A… |
10 mg |
15998-10 |
More Info
|
Luzindole |
A melatonin receptor antagonist that preferentially targets MT1B over MT1A… |
25 mg |
15998-25 |
More Info
|
Luzindole |
A melatonin receptor antagonist that preferentially targets MT1B over MT1A… |
5 mg |
15998-5 |
More Info
|
Luzindole |
A melatonin receptor antagonist that preferentially targets MT1B over MT1A… |
50 mg |
15998-50 |
More Info
|
Luzopeptin A |
A cyclic depsipeptide antibiotic that displays antitumor activity; acts as… |
1 mg |
18444-1 |
More Info
|
L-Valacyclovir-d8 (hydrochloride) |
An internal standard for the quantification of valacyclovir by GC- or LC-MS |
1 mg |
31479-1 |
More Info
|
L-Valacyclovir-d8 (hydrochloride) |
An internal standard for the quantification of valacyclovir by GC- or LC-MS |
500 µg |
31479-500 |
More Info
|
L-Valacyclovir (hydrochloride) |
A prodrug of acyclovir; inhibits HSV-I replication (IC50 = 0.84 µM);… |
100 mg |
23801-100 |
More Info
|
L-Valacyclovir (hydrochloride) |
A prodrug of acyclovir; inhibits HSV-I replication (IC50 = 0.84 µM);… |
25 mg |
23801-25 |
More Info
|
L-Valacyclovir (hydrochloride) |
A prodrug of acyclovir; inhibits HSV-I replication (IC50 = 0.84 µM);… |
250 mg |
23801-250 |
More Info
|
L-Valacyclovir (hydrochloride) |
A prodrug of acyclovir; inhibits HSV-I replication (IC50 = 0.84 µM);… |
50 mg |
23801-50 |
More Info
|
L-Valine |
An essential amino acid; considered glucogenic due to its catabolism that… |
100 g |
38709-100 |
More Info
|
L-Valine |
An essential amino acid; considered glucogenic due to its catabolism that… |
250 g |
38709-250 |
More Info
|
L-Valine |
An essential amino acid; considered glucogenic due to its catabolism that… |
500 g |
38709-500 |
More Info
|
L-Valine-d8 |
An internal standard for the quantification of L-valine by GC- or LC-MS |
1 mg |
34830-1 |
More Info
|
L-Valine-d8 |
An internal standard for the quantification of L-valine by GC- or LC-MS |
10 mg |
34830-10 |
More Info
|
L-Valine-d8 |
An internal standard for the quantification of L-valine by GC- or LC-MS |
25 mg |
34830-25 |
More Info
|
L-Valine-d8 |
An internal standard for the quantification of L-valine by GC- or LC-MS |
5 mg |
34830-5 |
More Info
|
LX2343 |
An inhibitor of BACE1 and PI3K (IC50s = 11.43 and 15.99 µM, respecti… |
1 mg |
27799-1 |
More Info
|
LX2343 |
An inhibitor of BACE1 and PI3K (IC50s = 11.43 and 15.99 µM, respecti… |
10 mg |
27799-10 |
More Info
|
LX2343 |
An inhibitor of BACE1 and PI3K (IC50s = 11.43 and 15.99 µM, respecti… |
5 mg |
27799-5 |
More Info
|
LXH254 |
A pan-RAF inhibitor; selectively inhibits B-RAF and C-RAF over a panel of… |
1 mg |
28231-1 |
More Info
|
LXH254 |
A pan-RAF inhibitor; selectively inhibits B-RAF and C-RAF over a panel of… |
10 mg |
28231-10 |
More Info
|
LXH254 |
A pan-RAF inhibitor; selectively inhibits B-RAF and C-RAF over a panel of… |
25 mg |
28231-25 |
More Info
|
LXH254 |
A pan-RAF inhibitor; selectively inhibits B-RAF and C-RAF over a panel of… |
5 mg |
28231-5 |
More Info
|
LX7101 (hydrochloride) |
A potent inhibitor of LIMK1, LIMK2, ROCK1, and ROCK2 kinases (IC50s = 32,… |
1 mg |
21209-1 |
More Info
|
LX7101 (hydrochloride) |
A potent inhibitor of LIMK1, LIMK2, ROCK1, and ROCK2 kinases (IC50s = 32,… |
10 mg |
21209-10 |
More Info
|
LX7101 (hydrochloride) |
A potent inhibitor of LIMK1, LIMK2, ROCK1, and ROCK2 kinases (IC50s = 32,… |
5 mg |
21209-5 |
More Info
|
LXR-623 |
An LXR modulator that acts as a partial agonist at LXRα and a full a… |
1 mg |
21117-1 |
More Info
|
LXR-623 |
An LXR modulator that acts as a partial agonist at LXRα and a full a… |
10 mg |
21117-10 |
More Info
|
LXR-623 |
An LXR modulator that acts as a partial agonist at LXRα and a full a… |
5 mg |
21117-5 |
More Info
|
LXS-196 |
A PKC inhibitor (IC50s = 1.9 and 0.4 nM for PKCα and PKCθ, res… |
1 mg |
31455-1 |
More Info
|
LXS-196 |
A PKC inhibitor (IC50s = 1.9 and 0.4 nM for PKCα and PKCθ, res… |
10 mg |
31455-10 |
More Info
|
LXS-196 |
A PKC inhibitor (IC50s = 1.9 and 0.4 nM for PKCα and PKCθ, res… |
25 mg |
31455-25 |
More Info
|
LXS-196 |
A PKC inhibitor (IC50s = 1.9 and 0.4 nM for PKCα and PKCθ, res… |
5 mg |
31455-5 |
More Info
|
LY171883 |
Potent, orally active CysLT receptor antagonist with KB values of 0.07 and… |
10 mg |
70710-10 |
More Info
|
LY171883 |
Potent, orally active CysLT receptor antagonist with KB values of 0.07 and… |
100 mg |
70710-100 |
More Info
|
LY171883 |
Potent, orally active CysLT receptor antagonist with KB values of 0.07 and… |
5 mg |
70710-5 |
More Info
|
LY171883 |
Potent, orally active CysLT receptor antagonist with KB values of 0.07 and… |
50 mg |
70710-50 |
More Info
|
LY2090314 |
A potent and selective inhibitor of GSK3 (IC50s = 1.5 and 0.9 for human re… |
1 mg |
22211-1 |
More Info
|
LY2090314 |
A potent and selective inhibitor of GSK3 (IC50s = 1.5 and 0.9 for human re… |
10 mg |
22211-10 |
More Info
|
LY2090314 |
A potent and selective inhibitor of GSK3 (IC50s = 1.5 and 0.9 for human re… |
25 mg |
22211-25 |
More Info
|
LY2090314 |
A potent and selective inhibitor of GSK3 (IC50s = 1.5 and 0.9 for human re… |
5 mg |
22211-5 |
More Info
|
LY2109761 |
A small molecule inhibitor of the TGF-β receptor type 1 / type II kin… |
1 mg |
15409-1 |
More Info
|
LY2109761 |
A small molecule inhibitor of the TGF-β receptor type 1 / type II kin… |
10 mg |
15409-10 |
More Info
|